Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma

被引：9

作者：

Kostakoglu, Lale ^{[1
]}

机构：

[1] Mt Sinai Med Ctr, Div Nucl Med, Dept Radiol, New York, NY 10029 USA

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2008年 / 35卷 / 08期

关键词：

D O I：

10.1007/s00259-008-0787-0

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

引用

页码：1413 / 1420

页数：8

共 55 条

[41]

NORTON L, 1988, CANCER RES, V48, P7067

[42] Survival benefit front high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma [J].

Pettengell, R ;

Radford, JA ;

Morgenstern, GR ;

Scarffe, JH ;

Harris, M ;

Woll, PJ ;

Deakin, DP ;

Ryder, D ;

Wilkinson, PM ;

Crowther, D .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :586-592

[43] AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS COMPARED WITH SALVAGE CHEMOTHERAPY IN RELAPSES OF CHEMOTHERAPY-SENSITIVE NON-HODGKINS-LYMPHOMA [J].

PHILIP, T ;

GUGLIELMI, C ;

HAGENBEEK, A ;

SOMERS, R ;

VANDERLELIE, H ;

BRON, D ;

SONNEVELD, P ;

GISSELBRECHT, C ;

CAHN, JY ;

HAROUSSEAU, JL ;

COIFFIER, B ;

BIRON, P ;

MANDELLI, F ;

CHAUVIN, F .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) :1540-1545

[44]

RIES LAG, 2006, SEER CANC STAT REV

[45] VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group [J].

Santini, G ;

Salvagno, L ;

Leoni, P ;

Chisesi, T ;

De Souza, C ;

Sertoli, MR ;

Rubagotti, A ;

Congiu, AM ;

Centurioni, R ;

Olivieri, A ;

Tedeschi, L ;

Vespignani, M ;

Nati, S ;

Soracco, M ;

Porcellini, A ;

Contu, A ;

Guarnaccia, C ;

Pescosta, N ;

Majolino, I ;

Spriano, M ;

Vimercati, R ;

Rossi, E ;

Zambaldi, G ;

Mangoni, L ;

Endrizzi, L ;

Sileni, VC ;

Miggiano, MC ;

Marino, G ;

Damasio, E ;

Rizzoli, V .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2796-2802

[46]

Schot BW, 2006, HAEMATOLOGICA, V91, P490

[47] A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].

SHIPP, MA ;

HARRINGTON, DP ;

ANDERSON, JR ;

ARMITAGE, JO ;

BONADONNA, G ;

BRITTINGER, G ;

CABANILLAS, F ;

CANELLOS, GP ;

COIFFIER, B ;

CONNORS, JM ;

COWAN, RA ;

CROWTHER, D ;

DAHLBERG, S ;

ENGELHARD, M ;

FISHER, RI ;

GISSELBRECHT, C ;

HORNING, SJ ;

LEPAGE, E ;

LISTER, TA ;

MEERWALDT, JH ;

MONTSERRAT, E ;

NISSEN, NI ;

OKEN, MM ;

PETERSON, BA ;

TONDINI, C ;

VELASQUEZ, WA ;

YEAP, BY .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994

[48] [18F]FDG PET monitoring of tumour response to chemotherapy:: does [18F]FDG uptake correlate with the viable tumour cell fraction? [J].

Spaepen, K ;

Stroobants, S ;

Dupont, P ;

Bormans, G ;

Balzarini, J ;

Verhoef, G ;

Mortelmans, L ;

Vandenberghe, P ;

De Wolf-Peeters, C .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (05) :682-688

[49] Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma [J].

Spaepen, K ;

Stroobants, S ;

Dupont, P ;

Vandenberghe, P ;

Thomas, J ;

de Groot, T ;

Balzarini, J ;

De Wolf-Peeters, C ;

Mortelmans, L ;

Verhoef, G .

ANNALS OF ONCOLOGY, 2002, 13 (09) :1356-1363

[50] Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease [J].

Straus, DJ ;

Portlock, CS ;

Qin, J ;

Myers, J ;

Zelenetz, AD ;

Moskowitz, C ;

Noy, A ;

Goy, A ;

Yahalom, J .

BLOOD, 2004, 104 (12) :3483-3489

← 1 2 3 4 5 6 →